TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression

Background: Breast cancer is the most common cancer in women worldwide. More than 70% of breast cancers are estrogen receptor (ER) alpha positive. Compared with ER alpha-negative breast cancer, which is more aggressive and has a shorter survival time, ER alpha-positive breast cancer could benefit from endocrine therapy. Selective estrogen receptor modulators, such as tamoxifen, are widely used in endocrine therapy. Approximately half of ER alpha-positive breast cancer patients will eventually develop endocrine resistance, making it a major clinical challenge in therapy. Thus, decoding the throughput of estrogen signaling, including the control of ER alpha expression and stability, is critical for the improvement of breast cancer therapeutics. Methods: TRIM3 and ER alpha protein expression levels were measured by western blotting, while the mRNA levels of ER alpha target genes were measured by RT-PCR. A CCK-8 assay was used to measure cell viability. RNA sequencing data were analyzed by Ingenuity Pathway Analysis. Identification of ER alpha signaling activity was accomplished with luciferase assays, RT-PCR and western blotting. Protein stability assays and ubiquitin assays were used to detect ER alpha protein degradation. Ubiquitin-based immunoprecipitation assays were used to detect the specific ubiquitination modification on the ER alpha protein. Results: In our current study, we found that TRIM3, an E3 ligase, can promote ER alpha signaling activity and breast cancer progression. TRIM3 depletion inhibits breast cancer cell proliferation and migration, while unbiased RNA sequencing data indicated that TRIM3 is required for the activity of estrogen signaling on the -genome-wide scale. The immunoprecipitation assays indicated that TRIM3 associates with ER alpha and promotes its stability, possibly by inducing K63-linked polyubiquitination of ER alpha. In conclusion, our data implicate a nongenomic mechanism by which TRIM3 stabilizes the ER alpha protein to control ER alpha target gene expression linked to breast cancer progression. Conclusion: Our study provides a novel posttranslational mechanism in estrogen signaling. Modulation ofTRIM3 expression or function could be an interesting approach for breast cancer treatment.

Automated summary

In this study, the researchers found that TRIM3, an E3 ligase, promotes ER alpha signaling activity and breast cancer progression. Depletion of TRIM3 inhibits breast cancer cell proliferation and migration, and unbiased RNA sequencing data showed that TRIM3 is crucial for estrogen signaling activity on a genome-wide scale. The researchers also demonstrated that TRIM3 associates with ER alpha and promotes its stability by inducing a specific ubiquitin modification. These findings provide a novel posttranslational mechanism in estrogen signaling and suggest that modulation of TRIM3 expression or function could be a promising approach for breast cancer treatment.